Articles tagged with Cancer Patients
Researchers at UCLA Health Jonsson Comprehensive Cancer Center developed a biobank of 294 samples from 126 patients with 25 different subtypes of bone and soft tissue sarcoma. The team created tumor organoids that retained key characteristics of the original tumors, which were then subjected to high-throughput drug screening. They iden...
A new study found that vulnerable patients treated at Commission on Cancer-accredited hospitals had a 9% lower mortality rate and were more likely to receive guideline-based care. This is attributed to CoC accreditation requirements for treatment guideline adherence, community engagement, and addressing barriers to care.
A phase 1b/2 clinical trial found a combination of immunotherapy and FGFR inhibitor to be safe and tolerable in patients with locally advanced or metastatic bladder cancer. The treatment showed increased response rates, including 54% for patients with high FGFR mRNA expression.
Researchers discovered ponsegromab, a monoclonal antibody, improves symptoms of cachexia by blocking the GDF-15 hormone. The treatment shows minimal side effects and boosts weight gain and patient activity in cancer patients.
A recent study found a correlation between higher anti-PD-1 autoantibody levels and lower survival rates in patients with advanced liver cancer, suggesting these autoantibodies as potential biomarkers for predicting treatment response. The discovery aims to improve treatment regimens for patients with liver cancer.
Researchers have developed a novel platform for testing radiation therapy effects on brain cells, providing insights into how the brain reacts to cancer treatment. The study aims to improve treatment strategies by understanding the impact of radiation on neural circuits, ultimately leading to personalized care for patients.
A clinical trial found that an oral cancer drug reduced nosebleed severity and improved quality of life in patients with hereditary hemorrhagic telangiectasia (HHT). The PATH-HHT study showed significant improvements in disease manifestations, including severe nosebleeds and chronic gastrointestinal bleeding.
A Northwestern University study finds that cancer patients prefer their providers assess their financial concerns early in treatment. Most patients (83%) want their providers to reach out regarding financial needs, with 82% preferring this at diagnosis or starting treatment.
A meta-analysis by Mass General Brigham researchers found that Black women face higher mortality rates from breast cancer across all tumor subtypes, attributed to socioeconomic inequality, delayed diagnosis, and inadequate access to timely quality treatment. This disparity is not limited to hormone-positive tumors, with differences als...
The CABINET trial demonstrates that cabozantinib significantly improves median progression-free survival (PFS) for patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. The treatment also shows promise across all clinical subgroups, including primary tumor site and grade.
Patients with low-risk cancers undergoing active surveillance experience anxiety caused by uncertainty, a problem that persists even after diagnosis, leading to negative responses such as fear and avoidance of decision-making. Medical interventions are needed to address this anxiety and improve patient-centered care.
A new clinical trial shows that immunotherapy treatment with pembrolizumab can significantly extend the cancer-free period for patients with high-risk, muscle-invasive bladder cancer. The study found that adjuvant pembrolizumab treatment nearly doubled the median length of time patients remained cancer-free compared to observation.
A double-blind randomized phase 3 clinical trial found no additional benefits from high-dose vitamin D3 when added to standard chemotherapy for patients with untreated metastatic colorectal cancer. However, a potential benefit was observed for left-sided disease patients.
Two studies found breastfeeding after breast cancer diagnosis is safe and feasible for young patients with specific genetic variations, as well as hormone receptor-positive breast cancer survivors. A third study shows a telephone-based coaching program can significantly increase physical activity in overweight patients, potentially imp...
The CheckMate 067 trial showed that combining nivolumab and ipilimumab improved outcomes for metastatic melanoma patients, with a median survival time over six years. Long-term follow-up found no new safety signals for the treatment, and metastatic melanoma survivors become increasingly likely to die of other causes as they age.
The RESILIENCE clinical trial explores the effectiveness of remote ischemic conditioning to prevent cardiotoxicity in lymphoma patients undergoing anthracycline-based chemotherapy. The trial aims to reduce heart failure prevalence and improve quality of life for cancer survivors.
A drug that delivers chemotherapy directly to tumors has shown substantial and durable activity in treating brain metastases of HER2-positive breast cancer. The treatment, trastuzumab deruxtecan, has improved progression-free survival and objective response rates in patients with advanced disease.
A study published in JAMA Network Open found that body mass index (BMI) has a more complex relationship with mortality risk during cancer therapy than previously thought. For patients with advanced non-small cell lung cancer, higher BMI was associated with lower mortality when undergoing immunotherapy or conventional chemotherapy. Howe...
CAR-T cell therapy, a regenerative immunotherapy, has shown promise in treating blood cancers but struggles with T-cell exhaustion. Researchers have discovered that overproduction of the IL-4 protein causes this exhaustion and used CRISPR gene-editing technology to remove it, improving CAR-T cell therapy outcomes.
A study by IRB Barcelona researchers has identified five independent factors that determine patients' response and survival after receiving checkpoint inhibitors, a type of immunotherapy. These findings provide a framework for current and future biomarkers of immunotherapy response and could lead to more accurate patient classification.
A groundbreaking study has provided novel insights into the molecular underpinnings of gastric cancer peritoneal spread, paving the way for more effective treatments. The research also demonstrated the safety and potential efficacy of a new treatment approach in a clinical trial.
A new study published in Annals of Oncology found that long-course radiotherapy is safer and more effective than short-course radiotherapy for preserving organs in rectal cancer patients. The treatment was shown to prevent regrowth of the primary tumour, but had similar overall survival rates.
Researchers at NTU Singapore and Oxford have identified a new process called nucleophagy that helps cells remove harmful DNA-protein lesions, promoting genetic material stability and cell survival. This discovery may improve cancer treatment outcomes for patients with colorectal cancer.
A recent study published in JAMA found that telehealth delivery of early palliative care is equivalent to in-person care in terms of quality of life outcomes for patients with advanced non-small cell lung cancer. This finding highlights the potential benefits of expanding access to this evidence-based care model through telehealth.
Researchers at WVU are working on a project to inhibit the myeloperoxidase enzyme, which feeds pancreatic cancer growth. By targeting this enzyme, they hope to boost the body's immune system to fight cancer, showing promise in mouse models and potential for future clinical trials.
New vaccines are being explored as a promising approach to treating glioblastoma, a highly lethal brain cancer with limited treatment options. These vaccines have been generally well-tolerated and have shown promise in improving survival rates for GBM patients.
Research found that first-degree relatives and spouses of cancer patients are at higher risk of developing psychological and cardiovascular illnesses. The study used data from the Utah Population Database to compare 77,938 relatives and spouses with 81,022 controls, finding a 10% increase in psychological condition risks and a 28% incr...
Researchers found that omitting the bolus-specific 5-fluorouracil (5-FU) portion from common chemotherapy regimens improves tolerability without sacrificing treatment effectiveness. The study of 11,765 patients shows no decrease in overall survival but a notable reduction in cytopenias.
A groundbreaking study published in Nature Medicine reports the first sustained remission of HIV infection following a bone marrow transplant in a patient without the CCR5-delta 32 mutation. Despite remaining susceptible to HIV, the virus remains undetectable nearly three years after antiretroviral treatment was stopped.
A University of Leicester study has found that certain gut bacteria may influence whether a patient's immune system is successful in fighting mesothelioma, an aggressive form of cancer. Researchers suggest that dietary changes, such as increased fibre intake, could improve the benefits of immunotherapy for these patients.
A team at NUS Yong Loo Lin School of Medicine leveraged an artificial intelligence-derived platform, CURATE.AI, to guide treatment for a patient with Waldenström macroglobulinemia, a rare blood disorder. The trial demonstrated substantial improvement in red blood cell levels and minimised side effects.
A Mass General Brigham-led study found that a large language model improves the accuracy of immune-related adverse event detection, identifying additional cases not picked up by manual adjudication. The model demonstrated excellent specificity and sensitivity, opening up opportunities for collaboration among institutions.
A recent study reveals racial disparities in cancer stage at diagnosis and survival for adolescents and young adults, highlighting the need for tailored interventions to achieve cancer care equity. The findings support health policy and funding implications, emphasizing the importance of addressing these disparities.
Researchers explore AI's role in addressing challenges in immunotherapy, developing new biomarkers for precise disease characterization and predicting treatment response. A comprehensive review applied AI/radiomics to cross-sectional imaging, showcasing the current landscape in IO treatment.
Women with regular annual mammograms had higher overall survival and lower late-stage cancer rates than those screened less frequently. The study's findings contradict current guidelines, suggesting a significant benefit to annual screening for women over 40.
A phase II clinical trial found that olaparib, a precision oncology drug, can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations. The study showed that 13 participants, including all 11 with BRCA2 mutations, had a decrease in PSA of at least 50% after treatment.
A new treatment approach has been confirmed effective in a major study, showing that locally advanced rectal cancer patients can experience complete tumour disappearance without needing surgery. This method reduces the risk of recurrence and preserves normal bowel function, offering a promising alternative to traditional treatments.
A systematic review and meta-analysis found that cognitive behavioral therapy (CBT) moderately improves mental health and quality of life in people with past or current cancer. CBT was more effective for younger individuals and in-person delivery compared to technology-based platforms.
A pivotal study supports belzutifan approval for patients with advanced kidney cancer, with belzutifan demonstrating a 25% lower risk of progression compared to everolimus. The HIF-2 inhibitor offers a novel therapeutic mechanism in advanced renal cell carcinoma treatment.
A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.
The Chinese College of Interventionalists has introduced a consensus statement on TACE refractoriness in hepatocellular carcinoma, providing a framework for clinicians to identify and manage the condition. This move aims to optimize treatment strategies and improve patient outcomes, particularly in China where HCC incidence is high due...
A new study by Korea University College of Medicine shows that direct-acting antivirals significantly reduce liver-related clinical outcomes and lower the risk of disease progression to cancer or cirrhosis, increasing life expectancy for patients with Hepatitis C. The treatment approach has a high effectiveness rate of 90%.
A recent review of 57,470 patient cases shows that rare cancer patients are nearly three times more likely to develop anxiety and depression compared to common cancer patients. The study highlights the need for early identification and intervention to address mental health risks in this group.
Patients with high-risk liver cancer who received neoadjuvant immunotherapy before surgery had comparable outcomes to those who received surgery upfront. Successful resection rates were higher among those treated with immunotherapy, leading to improved median recurrence-free survival.
The Ontario Institute for Cancer Research is providing nearly $6 million to eight research teams across Ontario, supporting studies that aim to diagnose and treat cancers more effectively. The Clinical Translational Pathway program will advance new discoveries and bring them to the healthcare system.
A new Cleveland Clinic study reveals that diet-derived molecules called metabolites are the main drivers of young-onset colorectal cancer risk, particularly those associated with red and processed meat. The research suggests that addressing diet with doctors can help prevent colon cancer in younger adults.
A Rice University-led team is developing an affordable system to improve tumor removal accuracy for breast and head and neck cancer. The AccessPath system enables rapid, automatic tumor margin classification, revolutionizing real-time surgical guidance.
Researchers at MUSC Hollings Cancer Center are developing a new model of care delivery to reach out to cancer survivors with depression, using a mobile app-based treatment called Moodivate that delivers behavioral activation. The grant aims to provide timely and tailored mental health treatment to this growing population.
Researchers uncovered how combining immunotherapies targeting PD1 and LAG3 enhances CD8+ T cell responses, leading to improved cancer-killing prowess and enhanced survival rates. The studies also revealed that relatlimab is not inert and can be combined with other immunotherapies to improve responses.
Researchers found that a simplified two-question test can predict smoking abstinence in cancer patients with equal accuracy as the full Fagerström Test. However, the test may not work well for Non-Hispanic Black people with a cancer diagnosis. The study aims to help doctors tailor tests for different groups.
A trial at UT Health San Antonio found that Sacituzumab Govitecan was well-tolerated and showed signs of effectiveness for patients with breast cancer who had progressed to brain tumors. The drug has been shown to deliver a topoisomerase inhibitor into tumors, providing promising clinical signals of efficacy.
Researchers identified a potential antigen for TCR recognition in melanoma, suggesting that RNLS protein could be recognized by T cells leading to local immune responses against the cancer. The study found that chemical complementarity between melanoma-resident TCR CDR3s and renalase-1 protein correlates with increased melanoma survival.
A new study suggests that MRI scans can help doctors identify patients with more aggressive prostate cancer, allowing for earlier treatment or active surveillance. The research found that suspicious lesions on an MRI test were associated with a higher risk of advanced disease in five years.
Researchers developed a drug that enhances killer T cells' fighting power while reducing the toxicity of unmodified IL-2 treatments, overcoming inhibitory Tr1 cells and increasing immunotherapy's effectiveness. The study aims to personalize cancer immunotherapy for more patients.
The study found that 29% of patients experienced progression-free survival at five years and 40% achieved overall survival. However, important survivorship issues were identified, including nonrelapse mortality rates of 16.2%, with over half occurring beyond two years post-treatment.
A recent study published in CANCER found that patients with metastatic non–small cell lung cancer treated with immunotherapy had improved overall and cancer-specific survival rates compared to those without it. The median overall survival was eight months, while cancer-specific survival was 10 months.
A research team has identified novel biomarkers in cervical mucus samples that show high diagnostic power for detecting cervical cancer. The findings suggest that analyzing local expression levels may offer a superior diagnostic strategy, potentially reducing the need for invasive procedures.
Researchers highlight acute need for mental health services and support for men with prostate cancer. The study found that 15% of prostate cancer patients started anti-anxiety and antidepression medications at diagnosis, while only 6% sought help from mental health services.
A new study found no racial or ethnic disparities in prior authorization outcomes for Black and Hispanic patients, but Asian patients had higher rates of approvals compared to White patients. The study analyzed data from 18,041 cancer patients diagnosed between 2017 and 2020.
A new AI protocol called DeepHRD enables accurate, instantaneous detection of cancer genomic biomarkers directly from tumor biopsy slides. This breakthrough technology saves weeks and thousands of dollars from clinical oncology treatment workflows, providing access and equity in cancer care for resource-constrained settings.